Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease

Boehringer Ingelheim1,588 enrolled

Overview

To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by * determination of the prevalence of depression in PD patients, based on MDI severity categories and the self-rating scale WHO-5, where poor well being was indicated. * exploration of influencing factors (PD status, therapeutic status) on the prevalence of MDI depression categories.

Study Type

OBSERVATIONAL

Enrollment

1,588

Conditions

Parkinson Disease

Eligibility

Sex: ALLMin age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. PD patients attending one of the participating neurologist practices during 2 fixed weeks in November 2008 2. Idiopathic PD with or without fluctuations 3. Male or female PD patients aged at least 30 4. Ability to reliably complete self-rating scales (WHO-5, MDI) ), according to the physician's judgement. 5. Written informed consent by the patient for study participation. Exclusion Criteria: 1. PD Patients who only attend the practice to get a prescription and are not seen by the doctor on that day 2. Patients who are not able to understand the questionnaires (e.g. due to mental impairment or language problems).

Locations (278)

Outcomes

Primary Outcomes

Prevalence of patients with depressive symptoms (based on WHO-5 and MDI) in total and in subgroups

Time frame: day 1

Secondary Outcomes

WHO-5 score and items

Time frame: day 1

MDI score (for a subgroup of patients with WHO-5 score < 13 or any WHO-5 item rated with 0 or 1)

Time frame: day 1

Correlation of WHO-5 and MDI (for a subgroup of patients with a WHO-5 score < 13 or any WHO-5 item rated with 0 or 1) in PD patients

Time frame: day 1

Investigator assessment of the applicability of the WHO-5 for screening for depression in PD patients

Time frame: day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Boehringer Ingelheim Investigational Site 1

Achim, Germany

Boehringer Ingelheim Investigational Site 2

Achim, Germany